This proposal is to evaluate the impact and cost effectiveness of combination HIVprevention interventions on population-level HIV incidence in Botswana, a country with a severegeneralized HIV epidemic. Despite a 25% prevalence in adults, Botswana has led Africa inscale-up of several interventions for HIV prevention and treatment. The proposal will use 16distinct, randomized rural communities to meet combination prevention goals of HIV Testingand Counseling (HTC), adult male circumcision (MC), AntiRetroviral Therapy (ART) forpatients with AIDS or CD4 d 250, and Prevention of Mother-to-Child Transmission (PMTCT).Eight control communities (Arm A) and 8 enhanced combination-prevention communities (ArmB) will be compared for HIV incidence, anticipating a reduction of e 50% over the study periodfor Arm B. A third (Arm C) in Mochudi will provide a step-wedge design with 6 communities toadd a 3-drug ART intervention for individuals with high viral-load ('high viral load carriers ')along with the enhanced combination prevention interventions used in Arm B, which weanticipate will provide even greater reductions in HIV incidence. All arms will evaluate HIV incidence over the 4-year study. Arms B and C will alsoinclude extensive extra activities, such as: community mobilization and education, enhancedHTC, mobile night clinics, linkage with various community organizations, and partner testing;extra testing techniques such as point-of-care CD4 testing to detect a larger fraction of patientswho qualify for ART and PMTCT; and earlier ART initiation and enhanced monitoring of thesame populations. For ART and PMTCT, we expect our targets to exceed those indicated in theRFA. The Botswana-Harvard Partnership (BHP) is a not-for-profit organization chartered underthe laws of Botswana, and is based upon a 15-year official collaboration between Harvard andthe Botswana Ministry of Health. In addition to serving as the original source agency to developthe Botswana PEPFAR and the National ART Program, as well as the largest AIDS-relatedtraining program in the country, the BHP has conducted scientific studies and extensivelypublished on all the major prevention interventions addressed in the RFA. The BHP also has alarge-capacity accredited laboratory that is central in location to the study sites and serves as thenational reference lab for HIV/AIDS.
While success has been obtained on treatment of HIV/AIDS in Africa with antiretroviral drugs (ARV) and on the prevention of transmission from mother to child, voluntary testing and counseling, and male circumcision, these interventions have not been adequately evaluated in combination for reduction of infection rates at the population level. We propose to do this in Botswana, a country with a very high prevalence of HIV, but also a record of governmental action on AIDS. We will also test a new use of ARV in adults with high viral loads who are most likely to transmit to others but do not qualify for the drugs based on disease status.
